Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab

Infectious Complications Associated With Immunomodulating Monoclonal Antibodies Used in the Treatment of Hematologic Malignancy

(2017) Sophia Koo et al.   Journal of the National Comprehensive Cancer Network

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

(2011) E. Doubrovina et al.   BLOOD

Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation

(2011) Austen Worth et al.   BRITISH JOURNAL OF HAEMATOLOGY

Neutropenia after rituximab treatment

(2011) Ofir Wolach et al.   CURRENT OPINION IN HEMATOLOGY

Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients

(2011) Hyo Jae Kang et al.   RESPIRATORY MEDICINE

Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell Transplantation

(2010) Stefania Coppoletta et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients

(2010) Nishitha Reddy et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts

(2010) M Hoegh-Petersen et al.   BONE MARROW TRANSPLANTATION

Intestinal Damage Determines the Inflammatory Response and Early Complications in Patients Receiving Conditioning for a Stem Cell Transplantation

(2010) Walter J. F. M. van der Velden et al.   PLoS One

Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation

(2010) Ben Carpenter et al.   TRANSPLANTATION

Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation

(2009) O. Landgren et al.   BLOOD

How I treat EBV lymphoproliferation

(2009) H. E. Heslop   BLOOD

Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children

(2009) M Faraci et al.   BONE MARROW TRANSPLANTATION

NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation

(2009) W J F M van der Velden et al.   BONE MARROW TRANSPLANTATION

Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction

(2009) H. Omar et al.   Transplant Infectious Disease

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases

(2009) J. Styczynski et al.   Transplant Infectious Disease

EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT

(2008) S Ocheni et al.   BONE MARROW TRANSPLANTATION

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia

(2008) J Styczynski et al.   BONE MARROW TRANSPLANTATION